Top Singapore Biotech Companies (41)
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element. Mice, test tubes, and other conventional preclinical models don't truly represent the complexities of the human body. Ninety percent of potential new drugs fail in humans because of the limited insight and misleading data generated in most preclinical drug studies. AIM's plug-and-play 3D cell culture systems change all of that: by enabling the equipment you already use in your lab to mimic the human microenvironment, your research project can get more predictive data at every stage. Make more informed decisions, save time, save resources. And to help you manage it, we also offer contract research services with the prestigious Institute of Molecular and Cell Biology—so you can benefit from our unique, human-focused approach to research in a world-class laboratory.
Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.
Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies.
Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers in Singapore, China and Brazil. We are continuously expanding our global footprint through cooperative R&D, investment, mergers and acquisitions. Focusing on oncology and chronic diseases, Virtue Diagnostics utilizes innovative technology platforms such as clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics to expand the China market. Through local capabilities built in emerging countries, Virtue is providing completed diagnostics menu cross biochemistry, chemiluminescence and molecular technologies.
Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, our experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives.
NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders’ personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics’ solutions are trusted by a growing number of healthcare providers, laboratories, insurers, and corporates in Asia and Europe. We have also won government grants and mandates to carry out genomic research projects from the Government of Singapore and others. These achievements reflect the company’s exceptional standards and depth of research as a scientist-led company, along with a commitment to delivering best-in-class genomic solutions. Find out more about us at www.nalagenetics.com
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. See our Community Guidelines: bit.ly/smcgl See our Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
Carcell Biopharma ("Carcell") is a global biotech company launched by EVX Ventures. With an innovative “hub-and-spoke” business model, Carcell accelerates innovations in and translation of next-generation cell and gene therapies. Carcell has two lead technology platforms. The first technological platform creates engineered red blood cells (eRBC) for allogeneic cell therapy against autoimmune diseases and cancer. The second technological platform is a lipid nanoparticle (LNP) platform that has a proprietary library and high throughput screening capabilities for effective nucleic acid delivery.
AMILI is a precision gut microbiome company based in Singapore, serving the region. Through AMILI's proprietary analytics engine, PRIME, we develop diagnostics tests, predictive algorithms and microbiome-modifying interventions. Our consumer health arm, BIO & ME, utilises insights from AMILI's database and PRIME to generate Asia-centric solutions towards personalised diet, supplementation and precision health. AMILI also houses Southeast Asia's first and only gut microbiome bank for clinical use and research. For more information, visit www.amili.asia.
X-ZELL is an award-winning medical technology start-up specialising in next-generation cytology. Cytology – or cytopathology – is the science of diagnosing diseases by examining single atypical cells or cell clusters. X-ZELL has developed a plug-and-play solution for the detection, visualization and digitization of these phenomena in minimally invasive body liquids. Slotting seamlessly into clinical routine, it does not require complex specimen preparation and reduces the average time from sample to diagnosis from 48h to less than 4h. The result: better diagnostics and improved patient care. X-ZELL is headquartered in Singapore and has regional offices in Germany (Europe), Thailand (Southeast Asia) and the US (North America).
Curiox Biosystems is committed to enabling accurate biological analysis through automation. Next-generation methods and applications--including single-cell 'omics technologies, flow cytometry, immunotherapy, and cell and gene therapy--deserve a next-generation approach to preparing samples for analysis. That’s why Curiox invented Laminar Wash technology, the only sample preparation method that eliminates centrifugation and the problems it introduces. The methodology keeps cells in their native state, improves cell retention and viability, and enhances reproducibility and miniaturization, ultimately leading to reduced costs and workflow standardization.
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives, one smile at a time. Discover your straight path to a bright future at Align. As a part of our smart, diverse and fast-moving global team, you'll make an impact for the market leader that's moving an industry forward. Want to find out what’s next for us—and for you?
Avant is the first cultivated fish company in Asia, with operations in Singapore and Hong Kong. Thanks to Avant's technology, we will be able to have fish meat without killing fish. Our cultivated fish products are more nutritious than conventionally produced fish, GMO-free, and pollutant-free. The pilot product focus of Avant's technology platform is fish and seafood tailored for the food culture of consumers in China and Asia.
About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability. We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and development efforts. This cutting-edge platform empowers us to swiftly explore numerous linker and payload combinations alongside our proprietary antibodies. We further harness state-of-the-art technologies, including an exclusive payload library derived from an FDA-approved drug and site-specific conjugation methods. These innovations are strategically employed to enhance the safety and quality of our ADCs. With two potential best-in-class programs on track for clinical trials by 2025 and a third program making headway toward IND status, we are poised for significant value creation and breakthroughs in cancer therapeutics. Based in Singapore, we plan to expand our clinical development operations to the United States by 2024. Join us on our journey to transform cancer treatment and make a meaningful impact in biotechnology. Axcynsis is at the forefront of developing life-changing ADC therapies, and we invite you to be a part of our innovative and dedicated team as we pioneer the future of cancer therapeutics.
Livestock disease prevention and sustainable agri productivity. Singaporean synbio startup funded by EF Venture Capital.
Work Your Passion. Live Your Purpose.
